Introduction
While many ocular diseases are limited to treatment of symptoms, an unmet medical need to treat the cause has been the driving force for a variety of ophthalmic drugs in pharmaceutical research and development. Several marketed drugs have been evaluated for topical ocular application (Chastain, 2003) . Ocular delivery and transport are well documented; however, ocular metabolism is not well studied. There is sparse evidence for drug metabolizing enzymes in ocular tissues of some animals, for example, ketoreductase (Lee et al., 1988) activity in rabbits, monoamine oxidase in cow (Sparks et al., 1981) , cytochrome P450 (P450) mRNA in rat (Nakamura et al., 2005) and human (Zhang et al., 2008) . Recently we reported a novel in vitro approach to investigate ocular metabolism (Bushee et al., 2015) in an effort to develop a simple, robust and reproducible model to study ocular disposition of xenobiotics across preclinical species and human.
Levobunolol (LB) [(S)-5-(3-(tert-butylamino)-2-hydroxypropoxy)-3,4-
dihydronaphthalen-1(2H)-one], is the levo-rotatory isomer of bunolol, a potent, nonselective antagonist of β -adrenergic receptors. Although it was initially aimed at cardiovascular pharmacodynamics (Novack, 1986) , LB has been utilized for treatment
achieved between 1 and 3 hours and the reduction of intraocular pressure is documented to last up to 12 hours with no reports of accumulation of the drug after repeated instillation. After systemic administration, LB showed a total plasma clearance of 0.66 L/hour and a large apparent volume of distribution equal to 5.5 L/kg. The elimination half-life was reported to be approximately 6 hours, and when applied topically at pharmacological doses, an accumulation index of 1 has been reported (Gonzalez and Clissold, 1987) .
LB has been reported to be metabolized to an equipotent active metabolite, dihydrolevobunolol (DHLB), with a similar systemic half-life. It has been reported that DHLB binds to beta adrenergic receptors with an affinity constant of 3.9 nM as compared to 6.7 nM for LB (Woodward et al., 1987) . In the eye, formation of DHLB is thought to occur deeper inside the corneal epithelium, and perhaps may be limited by passage of LB through the outer layers of corneal epithelium (Ashton et al., 1991) .
Besides investigation of DHLB formation, hepatic metabolism of LB has been reported in preclinical species and human. However, apart from formation of the active metabolite in corneal epithelium and iris-ciliary body (Lee et al., 1988) , LB has not been investigated in detail for its metabolism in the eye.
The objectives of the present investigation were to -(i) contrast the rate and extent of DHLB formation to overall metabolism of LB in ocular and liver sub-cellular fractions and (ii) investigate the role of ocular and hepatic non-P450 metabolism in the disposition of LB. To the best of our knowledge, our investigation is the first comprehensive documentation of in vitro ocular metabolism of LB in rat, rabbit, and Incubations with liver and ocular S9 fractions were performed in accordance with commonly accepted protocols and by modification of previously reported in vitro protocols (Dalvie et al., 2009 ). For parent depletion experiments, the final protein concentration of ocular S9 fractions (ROS9, RbtOS9 and HOS9) was 1.25 mg/mL and that of liver S9 fractions (RLS9, RbtLS9 and HLS9) was 0.31 mg/mL and the concentration of LB was 1 µM based on linearity with respect to protein and time (data not shown). The protein concentrations were consistent with the fact that levels of drug metabolizing enzymes are lower in extra-hepatic tissues and that an eye constitutes multiple complex cell types (Mohutsky et al., 2008) . For metabolite identification experiments, the final protein concentration of ocular S9 fractions (ROS9, RbtOS9 and HOS9) and liver S9 fractions (RLS9, RbtLS9 and HLS9) was 1.25 mg/mL and the concentration of LB was 10 µM in accordance with commonly accepted in vitro metabolite identification procedures (Dalvie et al., 2009; Gunduz et al., 2010) . The modifications specific to this study include the following for S9 fractions, alamethicin (25 µg/mg of protein), ethylene diamine tetra-acetic acid (0.1mM) were added to potassium phosphate buffer (100 mM, pH ~ 7.4) and placed on ice for 15 minutes. To this reaction mixture, MgCl 2 (1 mM), saccharolactone (5 mM), acetyl-CoA (1 mM), S-adenosyl methionine (0.1mM), 3'-Phosphoadenosine-5'-phosphosulfate (0.1 mM) were added and mixture was pre-incubated for 5 minutes at 37ºC in a shaking heating block At least 8 scans were collected across the LB peak area.
Materials and Methods

Chemicals and Reagents
LC-MS n method for LB depletion in ocular and liver S9 fractions
LC-MS n method for LB metabolite identification in ocular and liver S9 fractions
The samples generated for metabolite identification were analyzed with an Orbitrap-XL® mass spectrometer (Thermo Scientific) by a data-dependent scanning method with accurate mass measurements. Orbitrap-XL® was interfaced with a 3X Ti HPLC pump and a CTC PAL autosampler (Leap Technologies) as detailed in earlier reported protocols (Bushee and Argikar, 2011) M11 has a protonated m/z value of 294, 2 amu higher than parent. M11 was retained on column until 13.11 minutes. Accurate mass measurements strongly indicated the elemental composition to be C 17 H 27 NO 3 , suggesting a net addition of 2 hydrogen atoms compared to LB. CID MS/MS spectrum shows fragment ion m/z 220, which corresponds to the loss of water and the t-butyl group from [M+H] + ( Figure S1K ).
M11 was thus identified DHLB in liver and ocular S9 fractions in all species.
Structural rationalization of M1 through M10 and M12 through M16. Key MS/MS fragments for each metabolite and retention times are listed in Table 1 .
Identification of M1 (Supplemental Figure 1A) , M2 (Supplemental Figure 1B) ,M3
(Supplemental Figure 1C) , M4 (Supplemental Figure 1D ), M5(Supplemental Figure 1E) , Figure 1F ), M7(Supplemental Figure 1G ), M8 (Supplemental Figure   1H ), M9 (Supplemental Figure 1I ), M10 (Supplemental Figure 1J ), M11 (Supplemental Figure 1K ), M12 (Supplemental Figure 1L ), M13 (Supplemental Figure 1M ), M14
(Supplemental Figure 1N) , M15 (Supplemental Figure 1O) , and M16 (Supplemental Figure 1P ), based on MS/MS spectra is described in detail in supplemental figures.
Eleven of the sixteen metabolites of LB identified have never been previously reported.
This includes an acetylated primary metabolite of LB which was found in all ocular and liver fractions.
LB (1µM) depletion in ocular and liver S9 fractions.
RLS9 and RbtLS9 turned over LB such that approximately 40 percent or less remained after 60 minutes. Less than 15% LB turnover was observed in HLSS9, ROS9, RbtOS9, and HOS9 over an incubation period of 60 minutes. A parent depletion profile with respect to time is illustrated in Figure 3A .
Discussion
In the present investigation, we determined that LB was metabolized to sixteen different metabolites, eleven of which have never been reported. This is the first investigation that characterizes biotransformation pathways of LB in ocular subcellular fractions from rat, rabbit, and human, via non-CYP pathways, which have not been comprehensively investigated to date. Eleven of the sixteen metabolites of LB identified in this investigation have not been reported in the literature. This includes a direct acetyl conjugate of LB, which was observed in all ocular and liver fractions. Importantly, the study is the first report of six human ocular metabolites of LB. Our results indicated that liver was a poor in vitro surrogate for eye, and rat and rabbit were poor surrogates human in terms of the rate and extent of levobunolol metabolism. Overall, the rates of metabolism were remarkably lower in OS9 compared to LS9. The extent of metabolism of LB is illustrated as a schematic pathway in Figure 2 . No relationship was observed between rate and extent of metabolism of LB in subcellular fractions from either liver or eye for any species.
LB was metabolized via reduction to DHLB (M11) in all ocular and liver fractions.
In our experiments, the relative formation of M11, (as percentage of highest MS peak area) at the end of the incubation period was in the following order: RbtLS9 (1) > HOS9, HLS9(0.8) > RLS9(0.2) > RbtOS9(0.1) >> ROS9(0.01), as shown in Figure 3B .
Quantification of M11 was not possible without an authentic reference standard. Thus, formation of M11 was highest in RbtLS9, followed by that in HLS9, and HOS9. For human, comparable formation of M11 was observed between LS9 and OS9 fractions. fold lower than in RbtLS9. Collectively, these observations point toward organ and species differences in formation of M11 and also provide a new perspective on the increased duration of action of LB due to its active metabolite, DHLB (M11). M11 has previously been identified in urine of rat, dog, and human (Leinweber et al., 1977; Leinweber et al., 1978b; Leinweber et al., 1978a) . M11 has been reported as a pharmacologically active metabolite (Woodward et al., 1987) . Formation of DHLB has been characterized in rabbit corneal epithelium and iris-ciliary body in conjunction with trans-corneal passage of LB (Chen et al., 1987; Tang-Liu et al., 1987; Tang-Liu et al., 1988) . In the eye, ketone reductases have been shown to form DHLB from LB, as studied in rabbits (Lee et al., 1988; Ashton et al., 1991) .
We identified this metabolite even in liver S9 fractions from rat, rabbit, and human, suggesting a strong contribution of carbonyl reductases expressed in the liver.
Reduction of LB to M11 has been reported to occur in cytosol, but not microsomes and is NADPH (Lee et al., 1988) and pH dependent (Tang-Liu et al., 1988) . Overall the literature hints at a possible liver cytosolic role (Leinweber et al., 1972) and an even
has not been fully identified until now. It is also possible that the overall contribution of the corneal fractions to the formation of this metabolite may have been over-estimated in the previous reports. To the best of the authors' knowledge, the alternative hepatic enzymes described earlier have not been well characterized in ocular tissues. This finding on ocular and liver formation of M11 also needs to be taken into account for systemically administered LB and for accurate calculation of the fraction of topically (ocular) administered LB that escapes the eye into systemic circulation, as documented previously.
Additionally, DHLB (M11) was further metabolized to two hydroxylated metabolites, M4 in LS9 and M8 in OS9. Previously, a hydroxylated metabolite was identified in dog urine (Leinweber et al., 1977 The overall duration of action of DHLB, and in part LB, will depend on the net result of competing metabolic pathways for formation of DLHB in eye, liver, and other organs in combination with additional metabolic pathways leading to biotransformation of LB.
Two other monohydroxylated metabolites of LB were identified as M9 and M13.
M9 has been previously reported as urinary metabolite (Vollmer et al., 1986) , but M13 has never been reported until now. M12, a dihydroxylated metabolite of LB, with one site of hydroxylation confined to the 3-amino-2-hydroxypropoxy-3,4-dihydronaphthalen- Considerable species and organ specificity was observed in the in vitro metabolism of LB ( Figure 2 and Table 1 ). Both M1 and M10 were liver specific metabolites. While M10 was observed in LS9 from rat, rabbit, and human, M1 was only observed in RLS9 and RbtLS9. M9, M11 and M16 were observed in both liver and ocular fraction of all the species. In contrast, oxidative metabolites such as M4 and M13
were, present in RLS9 and HLS9, whereas M12 was present in RLS9 only. M7 and M8, two oxidative metabolites resulting from completely different biotransformation pathways, were present only in HOS9 and all LS9. Secondary metabolites illustrated
17 similar species and organ specificity. Overall, these metabolites and the observed biotransformation pathways suggest that liver metabolism is a poor surrogate for ocular metabolism. Our research thus far indicates that metabolism in the eye is best studied in ocular fractions for a given species of interest. Metabolism studies in the ocular and liver S9 fractions for rat and rabbit are likely to be complement those in human ocular and liver fractions.
In summary, our investigation presents a comprehensive documentation of metabolic fate of LB in ocular and liver S9 fractions from rat, rabbit and human. The present investigation documents a total of eleven new primary and secondary metabolites and thus presents new insights into metabolic pathways of a clinical drug. Incubations for metabolite identification were carried out at 10 µM LB concentration.
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